Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)
| Study (ref.) | CVD | Statin dose and comparator | Risk reduction (%) | Relative risk reduction (%) | Absolute risk reduction (%) | LDL cholesterol reduction (mg/dl) | LDL cholesterol reduction (%) |
|---|---|---|---|---|---|---|---|
| 4S-DM (215) | 2° | Simvastatin 20–40 mg vs. placebo | 85.7 to 43.2 | 50 | 42.5 | 186 to 119 | 36 |
| ASPEN 2° (220) | 2° | Atorvastatin 10 mg vs. placebo | 39.5 to 24.5 | 34 | 15 | 112 to 79 | 29 |
| HPS-DM (216) | 2° | Simvastatin 40 mg vs. placebo | 43.8 to 36.3 | 17 | 7.5 | 123 to 84 | 31 |
| CARE-DM (217) | 2° | Pravastatin 40 mg vs. placebo | 40.8 to 35.4 | 13 | 5.4 | 136 to 99 | 27 |
| TNT-DM (218) | 2° | Atorvastatin 80 mg vs. 10 mg | 26.3 to 21.6 | 18 | 4.7 | 99 to 77 | 22 |
| HPS-DM (216) | 1° | Simvastatin 40 mg vs. placebo | 17.5 to 11.5 | 34 | 6.0 | 124 to 86 | 31 |
| CARDS (221) | 1° | Atorvastatin 10 mg vs. placebo | 11.5 to 7.5 | 35 | 4 | 118 to 71 | 40 |
| ASPEN 1° (220) | 1° | Atorvastatin 10 mg vs. placebo | 9.8 to 7.9 | 19 | 1.9 | 114 to 80 | 30 |
| ASCOT-DM (219) | 1° | Atorvastatin 10 mg vs. placebo | 11.1 to 10.2 | 8 | 0.9 | 125 to 82 | 34 |
Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and nonfatal MI. In this tabulation, results of the statin on 10-year risk of major CVD endpoints (CHD death/nonfatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, PharmD, Oregon Health & Science University, 2007.